
FDA Tightens Restrictions on Lifesaving Duchenne Therapy Following Tragic Deaths
In a cautious move following two fatal cases, the FDA is significantly restricting the use of Elevidys, a gene therapy for Duchenne muscular dystrophy, highlighting the urgent need for safety in medical innovations that can deeply affect young lives.
Read full article






















